nach oben

Journal of Mammary Gland Biology and Neoplasia

Erschienen in:

01.12.2008

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

verfasst von: S. John Weroha, Paul Haluska

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

The insulin-like growth factor pathway plays a major role in cancer cell proliferation, survival and resistance to anti-cancer therapies in many human malignancies, including breast cancer. As a key signaling component of IGF system, the IGF-1 receptor is the target of several investigational agents in clinical and pre-clinical development. This review will focus on the rationale for targeting the IGF-1 receptor and other components of the IGF-1 system. In addition, we will examine the role of IGF-1 signaling in resistance to clinically important breast cancer therapies, including cytotoxic chemotherapy, hormonal therapy and erbB targeted agents. We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies.

Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA. 1993;90 23:11217–21. doi:10.1073/pnas.90.23.11217.PubMedCrossRef

Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 2005;65 9:3781–7. doi:10.1158/0008-5472.CAN-04-4602.PubMedCrossRef

Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002;1 4:339–53. doi:10.1016/S1535-6108(02)00055-7.PubMedCrossRef

Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev. 2005;16 4–5:407–20. doi:10.1016/j.cytogfr.2005.01.010.PubMedCrossRef

Hartog H, Wesseling J, Boezen HM, van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer. 2007;43 13:1895–904. doi:10.1016/j.ejca.2007.05.021.PubMedCrossRef

Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res. 2004;64 1:286–91. doi:10.1158/0008-5472.CAN-03-1242.PubMedCrossRef

Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 1990;50 21:6931–5.PubMed

Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006;444 7122:1038–43. doi:10.1038/nature05456.PubMedCrossRef

Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16 1:3–34. doi:10.1210/er.16.1.3.PubMedCrossRef

10.

Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271 34:20608–16. doi:10.1074/jbc.271.34.20608.PubMedCrossRef

11.

Rosenthal SM, Cheng ZQ. Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Natl Acad Sci USA. 1995;92 22:10307–11. doi:10.1073/pnas.92.22.10307.PubMedCrossRef

12.

Hamelers IH, van Schaik RF, Sipkema J, Sussenbach JS, Steenbergh PH. Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells. J Biol Chem. 2002;277 49:47645–52. doi:10.1074/jbc.M208727200.PubMedCrossRef

13.

Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272 5263:877–80. doi:10.1126/science.272.5263.877.PubMedCrossRef

14.

Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Cancer Invest. 2008;26 2:185–92. doi:10.1080/07357900701638343.PubMedCrossRef

15.

Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Schwartz P, et al. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol. 2006;103 3:990–5. doi:10.1016/j.ygyno.2006.06.006.PubMedCrossRef

16.

Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2008;17 7:1719–22. doi:10.1158/1055-9965.EPI-07-0654.PubMedCrossRef

17.

Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African–American and Hispanic women. Oncology 1999;57 4:330–40. doi:10.1159/000012052.PubMedCrossRef

18.

Haluska P, Shaw H, Batzel GN, Molife LR, Adjei AA, Yap TA, et al. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. ASCO Meeting Abstracts 2007;25 18_suppl:3586.

19.

Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26 8:1275–81. doi:10.1200/JCO.2007.14.4147.PubMedCrossRef

20.

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13 4:1198–207. doi:10.1158/1078-0432.CCR-06-1304.PubMedCrossRef

21.

Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res. 1999;5 7:1935–44.PubMed

22.

Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002;277 42:39684–95. doi:10.1074/jbc.M202766200.PubMedCrossRef

23.

Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab. 2001;86 3:972–9. doi:10.1210/jc.86.3.972.PubMedCrossRef

24.

Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19 5:3278–88.PubMed

25.

Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer. 2007;43 8:1318–27. doi:10.1016/j.ejca.2007.03.009.PubMedCrossRef

26.

Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;121 2:368–76. doi:10.1002/ijc.22697.PubMedCrossRef

27.

Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004;108 2:262–8. doi:10.1002/ijc.11544.PubMedCrossRef

28.

Wang HS, Wang TH. Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs). Chang Gung Med J. 2003;26 8:540–53.PubMed

29.

Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 1999;81 4:403–7. doi:10.1016/S0300-9084(99)80088-1.PubMedCrossRef

30.

Garrouste FL, Remacle-Bonnet MM, Lehmann MM, Marvaldi JL, Pommier GJ. Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells. Endocrinology 1997;138 5:2021–32. doi:10.1210/en.138.5.2021.PubMedCrossRef

31.

Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990;86 5:1503–10. doi:10.1172/JCI114868.PubMedCrossRef

32.

Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians. 1997;109 6:565–71.PubMed

33.

Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18 15:2471–9. doi:10.1038/sj.onc.1202600.PubMedCrossRef

34.

Munshi S, Hall DL, Kornienko M, Darke PL, Kuo LC. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr. 2003;59 Pt 10:1725–30. doi:10.1107/S0907444903015415.PubMedCrossRef

35.

Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004;5 3:231–9. doi:10.1016/S1535-6108(04)00051-0.PubMedCrossRef

36.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5 3:221–30. doi:10.1016/S1535-6108(04)00050-9.PubMedCrossRef

37.

Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008;27 11:1629–38. doi:10.1038/sj.onc.1210797.PubMedCrossRef

38.

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res. 2006;66 1:362–71. doi:10.1158/0008-5472.CAN-05-1107.PubMedCrossRef

39.

Karp DD, Paz-Ares LG, Blakely LJ, Kreisman H, Eisenberg PD, Cohen RB, et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2007;25 18_suppl:7506.

40.

Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997;57 13:2687–93.PubMed

41.

Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat. 1999;56 1:1–10. doi:10.1023/A:1006208721167.PubMedCrossRef

42.

Lee JY, Han CY, Yang JW, Smith C, Kim SK, Lee EY, et al. Induction of glutathione transferase in insulin-like growth factor type I receptor-overexpressed hepatoma cells. Mol Pharmacol. 2007;72 4:1082–93. doi:10.1124/mol.107.038174.PubMedCrossRef

43.

Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest. 1990;86 6:1806–14. doi:10.1172/JCI114910.PubMedCrossRef

44.

Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005;65 9:3868–76. doi:10.1158/0008-5472.CAN-04-3192.PubMedCrossRef

45.

Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer. 2002;101 1:11–6. doi:10.1002/ijc.10537.PubMedCrossRef

46.

Benini S, Manara MC, Baldini N, Cerisano V, Massimo S, Mercuri M, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res. 2001;7 6:1790–7.PubMed

47.

Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006;12 11 Pt 1:3532–40. doi:10.1158/1078-0432.CCR-05-1778.PubMedCrossRef

48.

Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001;92 1:37–45. doi:10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F.PubMedCrossRef

49.

MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50 2:151–96.PubMed

50.

Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8 6:215. doi:10.1186/bcr1612.PubMedCrossRef

51.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001;276 13:9817–24. doi:10.1074/jbc.M010840200.PubMedCrossRef

52.

Parisot JP, Hu XF, DeLuise M, Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer. 1999;79 5–6:693–700. doi:10.1038/sj.bjc.6690112.PubMedCrossRef

53.

Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146 11:4609–18. doi:10.1210/en.2005-0247.PubMedCrossRef

54.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005;11 5:2063–73. doi:10.1158/1078-0432.CCR-04-1070.PubMedCrossRef

55.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68 3:826–33. doi:10.1158/0008-5472.CAN-07-2707.PubMedCrossRef

56.

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93 24:1852–7. doi:10.1093/jnci/93.24.1852.PubMedCrossRef

57.

Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65 23:11118–28. doi:10.1158/0008-5472.CAN-04-3841.PubMedCrossRef

58.

Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther. 2008;7 9:2589–98. doi:10.1158/1535-7163.MCT-08-0493.PubMedCrossRef

59.

Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor Type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008;26 19:3196–203. doi:10.1200/JCO.2007.15.9319.PubMedCrossRef

60.

Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC. ASCO Meeting Abstracts 2008;26 15_suppl:8015.

61.

Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds JM, Lee AV, et al. Characterization of NSCLC patients responding to anti-IGF-IR therapy. ASCO Meeting Abstracts 2008;26 15_suppl:8000.

62.

Higano CS, Yu EY, Whiting SH, Gordon MS, LoRusso P, Fox F, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts 2007;25 18_suppl:3505.

63.

Olmos D, Okuno S, Schuetze SM, Paccagnella ML, Yin D, Gualberto A, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. ASCO Meeting Abstracts 2008;26 15_suppl:10501.

64.

Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F, et al. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). ASCO Meeting Abstracts 2008;26 15_suppl:3583.

65.

Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown H, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 2008;26 15_suppl:3519.

66.

Hidalgo M, Tirado Gomez M, Lewis N, Vuky JL, Taylor G, Hayburn JL, et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. ASCO Meeting Abstracts 2008;26 15_suppl:3520.

67.

Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias C, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advsanced cancer. ASCO Meeting Abstracts 2007;25 18_suppl:3590.

68.

Moreau P, Hulin C, Facon T, Boccadoro M, Mery-Mignard D, Deslandes A, et al. Phase I Study of AVE1642 Anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Blood 2007;110 11:1166. ASH Annual Meeting Abstracts.

69.

Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST). ASCO Meeting Abstracts 2008;26 15_suppl:3582.

70.

Harzstark AL, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B, et al. A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol (Meeting Abstracts) 2007;25 18_suppl:15500.

71.

Pollak MN, Lacy MQ, Lipton A, Demers L, Leitzel K, de Bono JS, et al. Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. ASCO Meeting Abstracts 2007;25 18_suppl:3587.

72.

Tolcher AW, Rothenberg ML, Rodon J, Delbeke D, Patnaik A, Nguyen L, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. ASCO Meeting Abstracts 2007;25 18_suppl:3002.

73.

Lacy M, Alsina M, Melvin CL, Roberts L, Yin D, Petersen JF, et al. Phase 1 first-in-human dose escalation study of cp-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor. J Clin Oncol (Meeting Abstracts) 2006;24 18_suppl:7609.

74.

Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, Brassil P, et al. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem. 2005;48 18:5639–43. doi:10.1021/jm050392q.PubMedCrossRef

75.

Parrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997;138 4:1427–33. doi:10.1210/en.138.4.1427.PubMedCrossRef

76.

Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989;84 5:1418–23. doi:10.1172/JCI114315.PubMedCrossRef

Titel: IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons
verfasst von: S. John Weroha
Paul Haluska
Publikationsdatum: 01.12.2008
Verlag: Springer US
Erschienen in: Journal of Mammary Gland Biology and Neoplasia / Ausgabe 4/2008
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-008-9104-6

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

Abstract

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

IGF Binding Proteins (IGFBPs) and Regulation of Breast Cancer Biology

Role of Insulin-Like Growth Factor Binding Proteins in Mammary Gland Development

Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis

The Role of Endocrine Insulin-Like Growth Factor-I and Insulin in Breast Cancer

IGF-I, GH, and Sex Steroid Effects in Normal Mammary Gland Development

Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Update Onkologie